April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Ocular Surface Inflammation and Azithromycin Ophthalmic Solution
Author Affiliations & Notes
  • Zahra Sadrai
    Ophthalmology/Harvard Med Sch, Schepens Eye Research Institute, Boston, Massachusetts
  • Yihe Chen
    Ophthalmology/Harvard Med Sch, Schepens Eye Research Institute, Boston, Massachusetts
  • Sunil Chauhan
    Ophthalmology/Harvard Med Sch, Schepens Eye Research Institute, Boston, Massachusetts
  • Reza Dana
    Ophthalmology/Harvard Med Sch, Schepens Eye Research Institute, Boston, Massachusetts
  • Footnotes
    Commercial Relationships  Zahra Sadrai, None; Yihe Chen, None; Sunil Chauhan, None; Reza Dana, None
  • Footnotes
    Support  Inspire Pharmaceuticals (R. Dana)
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 1124. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Zahra Sadrai, Yihe Chen, Sunil Chauhan, Reza Dana; Ocular Surface Inflammation and Azithromycin Ophthalmic Solution. Invest. Ophthalmol. Vis. Sci. 2011;52(14):1124.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the potential effects of azithromycin (AZM)in ameliorating dry eye disease (DED).

Methods: : Dry eye disease (DED) was induced in female C57BL/6 mice by exposing them to a controlled desiccating environment chamber. 1% AZM ophthalmic solution (AzaSite®; Inspire Pharmaceuticals, Inc, NC, USA) and relative vehicle were topically applied to different groups of DED mice (n = 8 eyes/group) 2x/daily. DED was scored by corneal fluorescein staining (CFS). CD11b+ infiltration was evaluated by immunohistochemistry. Expression level of cytokine IL-1β was quantified by real-time PCR.

Results: : Compared to the vehicle control, the AZM-treated group showed a reduction in CFS at days 5 and 14 by 36% (P=0.0002) and 19% (P=0.1), respectively. The expression level of inflammatory cytokine IL-1β was decreased by half at day 14 in the AZM treated group. There was no significant difference in CD11b+ cell infiltration between treated and untreated groups.

Conclusions: : Following DED induction, topical AZM reduces the progression of DED at days 5 and 14. This was supported by a reduction in IL-1β expression. This data suggest that topical AZM could be an effective therapeutic modality for the DED treatment.Research support: Inspire Pharmaceuticals (R. Dana)

Keywords: cornea: tears/tear film/dry eye • inflammation • immunomodulation/immunoregulation 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×